Investor Presentaiton
Summary of Drive 2022 (FY2020-2022)
Medical
Business
SEKISUI
■Steadily expanded the Diagnostics Business in Japan and overseas; expanded sales of
COVID-19 diagnostics kits, secured contributions to earnings also from new pharmaceutical
ingredients, and growth in line with the Medium-term Management Plan; achieved record-high
profit for two consecutive fiscal years
Three Business Net Sales
(JPY billion)
Priority Implementation Measures
FY19
Results
FY22
Results
FY19→
FY22
Difference
FY22
Medium-
tem plan
Difference
from the
Medium-
term Plan
Item
Measures
Growth
initiatives
Strategic
investments
Total Medical
72.6
89.7
+17.1
85.0
+4.7
business
Diagnostics
28.5
30.9
+2.4
32.0
-1.1
(Japan)
Diagnostics
30.3
41.2
+10.9
36.8
+4.4
(Overseas)
New
products
•
•
Pharmaceutical
13.6
17.6
+4.0
18.2
-0.6
Sciences
Structural
reforms
Analysis of Operating Profit
(JPY billion)
Consoli-
dated-
basis Foreign
Change Exchange (Japan)
Diagno-
stics
Diagno- Pharmaceutical
stics
(overseas)
Science and Fixed
Other
Costs
Total
Deference
0
+1.9
-2.2
-1.1
+0.4
+0.9
0
12.5
FY2022
Medium-term Plan
Copyright@ SEKISUI CHEMICAL CO., LTD.
0
.
.
Commence new facility operations at
the Group's Pharmaceuticals Iwate
Factory
• Promote progress at the Group's GMP-
•
compliant enzyme U.K. factory
Accelerate gene testing development in
the U.S.
Blood coagulation testing equipment
Reagents for rapid COVID-19 and
influenza testing use
• Transfer of XenoTech shares
12.5
FY2022
Results
Results and Challenges
Diagnostics (Japan)
•
•
Results: Expanded sales of COVID-19 diagnostics kits
Challenges: Delays in expanding new products; new blood
coagulation testing equipment sales growth
Diagnostics (Overseas)
•
Results: Steadily expanded in Europe, the U.S., and China;
established a gene development system
• Challenges: Strengthening U.S. FDA compliance; rebuild
operations in Asia
Pharmaceutical Sciences
•
•
Results: Secured large new pharmaceutical orders; completed
construction of a new facility at the Group's Iwate Factory;
promoted structural reforms
Challenges: Establish the Drug Development Solutions
Business; CDMO Business expansion
39View entire presentation